Drugs / BBP-398
BBP-398
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06032936 | Jul 2023 → Mar 2024 | non-small cell lung carcinoma | LianBio LLC | Terminated | No outcome recorded |
| Phase 1 | NCT05375084 | Oct 2022 → Apr 2024 | non-small cell lung carcinoma | Navire Pharma Inc., a BridgeBio company | Terminated | No outcome recorded |
| Phase 1 | NCT05621525 | Oct 2022 → Mar 2024 | non-small cell lung carcinoma | LianBio LLC | Terminated | No outcome recorded |
| Phase 1 | NCT05480865 | Jul 2022 → Aug 2024 | metastatic malignant neoplasm, non-small cell lung carcinoma | Navire Pharma Inc., a BridgeBio company | Terminated | No outcome recorded |
| Phase 1 | NCT04528836 | Nov 2020 → Mar 2024 | — | Navire Pharma Inc., a BridgeBio company | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06024174 | Nov 2023 → May 2024 | cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBP-398 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05621525 ↗ |
| Known as | BMS-986466 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06024174 ↗ |
| Known as | IACS-15509 | “BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2” NCT06032936 ↗3“SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509)” NCT05480865 ↗ “BBP-398 (Formerly known as IACS-15509)” NCT04528836 ↗ “BBP-398 (Formerly Known as IACS-15509)” NCT05375084 ↗ |
| Action | Inhibit | “a SHP2 inhibitor” NCT04528836 ↗ |
| Modality | Small molecule | — CHEMBL5761940 ↗ |
| Route | Oral | “Oral capsules taken in escalating levels” NCT04528836 ↗ |